# ZYMEDI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zymedi

- Industry: Biotechnology
- Headquarters: Incheon, South Korea
- Website: www.zymedi.com/
- Total disclosed funding: $29M
- Latest round: Series A (May 30, 2023)
- Investors on record: 8

## About

Established in 2019 and based in Incheon, South Korea, Zymedi operates as a biotechnology company that develops pharmaceutical drugs and novel therapeutics for diseases. Sunghoon Kim (CEO) and Nam Hoon Kwon (CTO) are the co-founders of the company. In January 2025, ZYMEDI received USD 4.5 million of grant funding from new investor Korea Institute for Advancement of Technology.

The company provides HOMEOS (AIDD), which is a platform that harnesses knowledge of aminoacyl-tRNA synthetase (ARS) biology to maintain a varied pipeline of medications. The firm has a proprietary database that contains all ARS-related information. The Darsome database provides in-depth investigation of disease-associated ARS genome and proteome alterations, while the Inter-ARS database provides insights into the ARS interactome. Zymedi also makes use of the Ailo database, an AI-based lead optimisation tool for druggable candidates.

ZYMEDI's pipeline includes an antibody for pulmonary arterial hypertension (PAH) that specifically targets membrane-exposed lysyl-tRNA synthetase (KARS1). In addition, the company is developing a small-molecule chemical that inhibits KARS1's multifarious proinflammatory activities for the treatment of non-alcoholic steatohepatitis (NASH). Furthermore, ZYMEDI's pipeline includes a pan-KRAS inhibitor targeted to target AIMP2-DX2 in KRAS-mutated tumours.

The company will use the January 2025 funding to support the creation of treatments for lung conditions.

## Funding rounds

- Series A, May 30, 2023, $12M — Korea Development Bank, CKD Venture Capital, Atinum Investment, IMM Investment, Company K Partners, UTC Investment, Medytox Venture Investment, Korea Venture Investment Corporation
- Series A, Mar 1, 2021, $17M — Atinum Investment, Company K Partners, UTC Investment

## Investors

- Atinum Investment (https://capitalatlas.ai/funds/atinum-investment) — Series A
- Company K Partners (https://capitalatlas.ai/funds/company-k-partners) — Series A
- UTC Investment (https://capitalatlas.ai/funds/utc-investment) — Series A
- Korea Development Bank (https://capitalatlas.ai/funds/korea-development-bank) — Series A
- CKD Venture Capital (https://capitalatlas.ai/funds/ckd-venture-capital) — Series A
- IMM Investment (https://capitalatlas.ai/funds/imm-investment) — Series A
- Medytox Venture Investment (https://capitalatlas.ai/funds/medytox-venture-investment) — Series A
- Korea Venture Investment Corporation (https://capitalatlas.ai/funds/korea-venture-investment-corporation) — Series A